市場調査レポート
商品コード
231905

癌領域における各種提携契約:契約動向・企業・財務条件

Oncology Collaboration and Licensing Deals 2019-2023

出版日: | 発行: Current Partnering | ページ情報: 英文 1600+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.28円
癌領域における各種提携契約:契約動向・企業・財務条件
出版日: 2023年10月01日
発行: Current Partnering
ページ情報: 英文 1600+ Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、癌領域における各種提携契約について調査し、近年の提携契約の動向、取引タイプ・開発段階・技術・適応症など各種区分別の内訳、提携契約の財務的条件、主な大型契約、提携契約に積極的な企業、契約文書のディレクトリーなどをまとめています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 癌関連の各種契約動向

  • イントロダクション
  • 過去の提携動向
  • 提携動向:取引タイプ別
  • 提携動向:産業部門別
  • 提携動向:開発段階別
  • 提携動向:技術タイプ別
  • 提携動向:適応症別

第3章 提携契約の財務条件

  • イントロダクション
  • 開示されている財務条件
  • 契約総額
  • 前払い金
  • マイルストーン (目標到達毎) 支払い金
  • ロイヤルティレート

第4章 主な提携契約・契約者

  • イントロダクション
  • 提携にもっとも活発な事業者
  • もっとも活発な事業者のリスト
  • 主要契約:契約額別

第5章 契約文書ディレクトリー

  • イントロダクション
  • 文書が開示されている提携契約

第6章 契約動向:治療標的別

  • イントロダクション
  • 契約動向:治療標的別

付録

目次
Product Code: CP2201

Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of oncology deals from 2019 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2019
  • Browse oncology collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Oncology Collaboration and Licensing Deals includes:

  • Trends in oncology dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of oncology deal records covering pharmaceutical and biotechnology
  • The leading oncology deals by value
  • Most active oncology licensing dealmakers

In Oncology Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2019
  • Browse oncology collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

  • 2.1. Introduction
  • 2.2. Oncology partnering over the years
  • 2.3. Oncology partnering by deal type
  • 2.4. Oncology partnering by industry sector
  • 2.5. Oncology partnering by stage of development
  • 2.6. Oncology partnering by technology type
  • 2.7. Oncology partnering by therapeutic indication

Chapter 3 - Financial deal terms for oncology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for oncology partnering
  • 3.3. Oncology partnering headline values
  • 3.4. Oncology deal upfront payments
  • 3.5. Oncology deal milestone payments
  • 3.6. Oncology royalty rates

Chapter 4 - Leading oncology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in oncology partnering
  • 4.3. List of most active dealmakers in oncology
  • 4.4. Top oncology deals by value

Chapter 5 - Oncology contract document directory

  • 5.1. Introduction
  • 5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by oncology therapeutic target
  • Deal directory
  • Deal directory - Oncology deals by company A-Z 2019 to 2023
  • Deal directory - Oncology deals by technology type 2019 to 2023
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Oncology partnering since 2019
  • Figure 2: Oncology partnering by deal type since 2019
  • Figure 3: Oncology partnering by industry sector since 2019
  • Figure 4: Oncology partnering by stage of development since 2019
  • Figure 5: Oncology partnering by technology type since 2019
  • Figure 6: Oncology partnering by indication since 2019
  • Figure 7: Oncology deals with a headline value
  • Figure 8: Oncology deals with upfront payment values
  • Figure 9: Oncology deals with milestone payment
  • Figure 10: Oncology deals with royalty rates
  • Figure 11: Active oncology dealmaking activity since 2019
  • Figure 12: Top oncology deals by value since 2019